Mural im La Mission District San Francisco (Aufnahme Oncoletter)
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Für eine vollständige Ansicht aller 30 Abstract-Titel nutzen Sie bitte die Desktop-Version von Oncoletter
Link to Abstracts
Link to Posters: Sie müssen bei ASCO-GI eingeloggt sein und über eine aktuelle Registrierung verfügen, um auf die Poster dieser Sitzung zugreifen zu können. Hier können Sie die Registrierung erwerben.
- FOENIX-CCA4: A phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements.
- Glutamine antagonist DRP-104 in combination with durvalumab in patients with advanced fibrolamellar carcinoma (FLC) following progression on prior anti-PD(L)1 therapy.
- Sequential or up-front triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma (HCC): MONTBLANC.
- First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory/relapsed cholangiocarcinoma.
- An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab plus bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
- A phase 1b/2 study to evaluate the safety and efficacy of TTI‑101 as monotherapy and in combination in advanced hepatocellular carcinoma.
- Lenvatinib in recurrent hepatocellular carcinoma after liver transplantation.
- Anlotinib combined with penpulimab and hepatic artery infusion chemotherapy (HAIC) in the first-line treatment of unresectable hepatocellular carcinoma.
- FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
- Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.
- A phase II study to evaluate the safety and efficacy of anlotinib combined with penpulimab for advanced refractory biliary tract cancer.
- ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer.
- Atezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC.
- PRECISION 1: A phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2.
- Phase II study evaluating the efficacy of PDS0301 in combination with hepatic artery infusion pump (HAIP) and systemic therapy for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma.
- A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.
- Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas.
- Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma.
- Epidemiological characteristics of gastric and pancreatic cancers in Latin America: The LACOG 0222 GASPAR study.
- DIsCOvER: A multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of dronabinol in the improvement of chemotherapy-induced and tumor-related symptoms in patients with locally advanced or metastatic pancreas cancer during first-line chemotherapy.
- A phase 1b/2 trial of pepinemab and avelumab as second line therapy for patients with metastatic pancreatic adenocarcinoma.
- A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC).
- AIRPanc: A phase 2, open-label, multicenter, randomized study evaluating neoadjuvant therapy targeting the adenosine immunosuppressive pathway in combination with immune checkpoint blockade and radiation therapy in patients with advanced pancreatic ductal adenocarcinoma who are candidates for surgical resection.
- A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies.
- COVALENT-102: A phase 1/1b dose finding study of BMF-219, an oral covalent menin inhibitor, in adults with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC), pancreatic cancer (PDAC) and colorectal cancer (CRC) with activating KRAS mutations.
- A phase II telemedicine study of pemigatinib in adult patients with unresectable or metastatic pancreas cancer with FGFR2 gene fusions or other FGFR genetic alterations.
- PANOVA-4 (EF-39): Pilot study of tumor treating fields (TTFields) therapy with atezolizumab, gemcitabine (GEM), and nab-paclitaxel (NabP) as first-line (1L) treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).
- A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).
- AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma.
- Multicenter study of circulating tumor DNA in patients with pancreatic cancer using a personalized panel: ARTEMIS-PC prospective observational trial.
Presenter: Teresa Macarulla, MD, PhD | Department of Medical Oncology, Vall d´Hebrón University Hospital, Vall d´Hebrón Institute of Oncology (VHIO)
TPS572 FOENIX-CCA4: A phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements.
Für Hintergrund und Methoden siehe Abstract
Presenter: Mari Nakazawa, MD, MHS | Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
TPS573 Glutamine antagonist DRP-104 in combination with durvalumab in patients with advanced fibrolamellar carcinoma (FLC) following progression on prior anti-PD(L)1 therapy.
Für Hintergrund und Methoden siehe Abstract
Presenter: Lorenza Rimassa, MD | Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospit
TPS574 Sequential or up-front triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma (HCC): MONTBLANC.
Für Hintergrund und Methoden siehe Abstract
Presenter: Milind M. Javle, MD | Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center
TPS575 First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory/relapsed cholangiocarcinoma.
Für Hintergrund und Methoden siehe Abstract
Presenter: Kevin Kim, MD, MHS | University of Maryland School of Medicine
Presenter: Farshid Dayyani, MD, PhD | Division of Hematology/Oncology, Department of Medicine, University of California, Irvine
TPS577 A phase 1b/2 study to evaluate the safety and efficacy of TTI‑101 as monotherapy and in combination in advanced hepatocellular carcinoma.
Für Hintergrund und Methoden siehe Abstract
Presenter: Mehmet Akce, MD | Division of Hematology/Oncology, University of Alabama at Birmingham
TPS578 Lenvatinib in recurrent hepatocellular carcinoma after liver transplantation.
Für Hintergrund und Methoden siehe Abstract
Presenter: Gong-Rang Chen | Yiyang Central Hospital
TPS579 Anlotinib combined with penpulimab and hepatic artery infusion chemotherapy (HAIC) in the first-line treatment of unresectable hepatocellular carcinoma.
Für Hintergrund und Methoden siehe Abstract
FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and o
TPS580 FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
Für Hintergrund und Methoden siehe Abstract
Presenter: Raed Moh'd Taiseer Al-Rajabi, MD | University of Kansas Cancer Center
TPS581 Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.
Für Hintergrund und Methoden siehe Abstract
Presenter: Xiaojun He | General Surgery Department, The Second Affiliate Hospital of Air Force Medical University/Tangdu Hospital
TPS582 A phase II study to evaluate the safety and efficacy of anlotinib combined with penpulimab for advanced refractory biliary tract cancer.
Für Hintergrund und Methoden siehe Abstract
Presenter: Thorsten Goetze, Prof. Dr. | Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, UCT-University Cancer Center & Frankfurter IKF
TPS583 ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer.
Für Hintergrund und Methoden siehe Abstract
Presenter: Stacey Stein, MD | Yale Cancer Center
TPS584 Atezolizumab and bevacizumabin combination with TACE for patients with BCLC B HCC.
Für Hintergrund und Methoden siehe Abstract
Presenter: Dustin A. Deming, MD | University of Wisconsin Carbone Cancer Center
TPS585 PRECISION 1: A phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2.
Für Hintergrund und Methoden siehe Abstract
Presenter: Jonathan Matthew Hernandez, MD | National Cancer Institute
Presenter: Olivia Aranha, MD, PhD | Washington University School of Medicine in St. Louis
TPS587 A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.
Für Hintergrund und Methoden siehe Abstract
Presenter: Michael J. Demeure, MD, MBA | Hoag Memorial Hospital Presbyterian, Translational Genomics Research Institute
TPS601 Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas.
Für Hintergrund und Methoden siehe Abstract
Presenter: Patrick Walsh McGarrah, MD | Mayo Clinic
TPS602 Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma.
Für Hintergrund und Methoden siehe Abstract
Presenter: Renata D'Alpino Peixoto, MD | Grupo Oncoclínicas
TPS710 Epidemiological characteristics of gastric and pancreatic cancers in Latin America: The LACOG 0222 GASPAR study.
Für Hintergrund und Methoden siehe Abstract
Presenter: Meinolf Karthaus, MD | Department of Hematology and Oncology, Munich Hospital Neuperlach
TPS711 DIsCOvER: A multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of dronabinol in the improvement of chemotherapy-induced and tumor-related symptoms in patients with locally advanced or metastatic pancreas cancer during first-line chemotherapy.
Für Hintergrund und Methoden siehe Abstract
Presenter: Bailey Hilty, MD | University of Rochester Cancer Center & Wilmot Cancer Institute
TPS712 A phase 1b/2 trial of pepinemab and avelumab as second line therapy for patients with metastatic pancreatic adenocarcinoma.
Für Hintergrund und Methoden siehe Abstract
Presenter: Peter Joel Hosein, MD | University of Miami Sylvester Comprehensive Cancer Center
TPS713 A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC).
Für Hintergrund und Methoden siehe Abstract
Presenter: Gulam Abbas Manji, MD, PhD, PhD (c) | Columbia University Herbert Irving Comprehensive Cancer Center
TPS714 AIRPanc: A phase 2, open-label, multicenter, randomized study evaluating neoadjuvant therapy targeting the adenosine immunosuppressive pathway in combination with immune checkpoint blockade and radiation therapy in patients with advanced pancreatic ductal adenocarcinoma who are candidates for surgical resection.
Für Hintergrund und Methoden siehe Abstract
Presenter: Brian Hemendra Ramnaraign, MD | University of Florida/UF Health Cancer Center
TPS715 A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies.
Für Hintergrund und Methoden siehe Abstract
Presenter: Christos Fountzilas, MD, FACP | Roswell Park Comprehensive Cancer Center
TPS716 COVALENT-102: A phase 1/1b dose finding study of BMF-219, an oral covalent menin inhibitor, in adults with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC), pancreatic cancer (PDAC) and colorectal cancer (CRC) with activating KRAS mutations.
Für Hintergrund und Methoden siehe Abstract
Presenter: Zachary Risch, MD | The Ohio State University
TPS717 A phase II telemedicine study of pemigatinib in adult patients with unresectable or metastatic pancreas cancer with FGFR2 gene fusions or other FGFR genetic alterations.
Für Hintergrund und Methoden siehe Abstract
Presenter: Thomas Seufferlein, MD | Universitätsklinikum Ulm
TPS718 PANOVA-4 (EF-39): Pilot study of tumor treating fields (TTFields) therapy with atezolizumab, gemcitabine (GEM), and nab-paclitaxel (NabP) as first-line (1L) treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).
Für Hintergrund und Methoden siehe Abstract
Presenter: Anup Kasi, MD, MPH | University of Kansas Cancer Center
TPS719 A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).
Für Hintergrund und Methoden siehe Abstract
Presenter: Zev A. Wainberg, MD | UCLA School of Medicine
TPS720 AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma.
Für Hintergrund und Methoden siehe Abstract
Presenter: Edward D. Esplin, MD, PhD, FACP, FACMG | Invitae
TPS721 Multicenter study of circulating tumor DNA in patients with pancreatic cancer using a personalized panel: ARTEMIS-PC prospective observational trial.
Für Hintergrund und Methoden siehe Abstract
Copyright 2025. All Rights Reserved.